Blueprint Medicines — Technical Presentation (September 2017)
16 slides from Blueprint Medicines's technical presentation, Sep 11, 2017
Slide 1: Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma
Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma Richard Kim1, Debashis Sarker2, Teresa Macarulla3, Thomas Yau4, Su Pin Choo5, Tim Meyer6, Antoine Hollebecque7, Jonathan Whisenant8, Max Sung9, Jung-Hwan Yoon10, Ho Yeong Lim11, Andrew Zhu12, Joong-Won Park13, Sandr
Slide 2: Disclosures
BLU-554 is an investigational agent currently in development by Blueprint Medicines Corporation (Blueprint Medicines) Dr Richard Kim is an investigator for Blueprint Medicines’ ongoing Phase 1 studies in advanced HCC Dr Richard Kim has the following disclosures: Research: Blueprint Medicines, Bayer,
Slide 3: Hepatocellular Carcinoma (HCC) and FGF19
Hepatocellular Carcinoma (HCC) and FGF191-4 3 FGFR4, fibroblast growth factor receptor 4; FGF19, fibroblast growth factor 19; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; KLB, klotho-β Multi-kinase inhibitors provide OS < 1 year FGF19 - a potential HCC driver FGF19 is a mitog
Slide 4: BLU-554: a potent and highly selective FGFR4 inhibitor for HCC
BLU-554: a potent and highly selective FGFR4 inhibitor for HCC 5 BLU-554 Sorafenib Regorafenib Inhibitory Mechanism TEL-FGFR4 IC50 nM Cellular BLU-554 Type 1 Irreversible 3.5 sorafenib Type 2 Reversible 4,142 regorafenib Type 2 Reversible 3,021 LIX-066 PDX model FGF19 overexpression without amplific
Slide 5: BLU-554: first-in-human study
Key objectives Define MTD, safety profile, pharmacokinetics and pharmacodynamics Assess preliminary anti-tumor activity in relation to FGF19 IHC and FISH status BLU-554: first-in-human study 5 NCT02508467 ECOG PS, Eastern Cooperative Oncology Group performance status; MTD, maximum tolerated dose Par
Slide 6: FGF19 immunohistochemistry (IHC) identifies aberrant pathway activation
FGF19 immunohistochemistry (IHC) identifies aberrant pathway activation 6 107/395 FGF19 IHC+ ≥ 1% Aberrant pathway activation in 27% Central Laboratory IHC IHC-negative 0% IHC+ 1% IHC+ 15% IHC+ 50% Data are preliminary as of data cut off: 18 August 2017 277 107 11 0 50 100 150 200 250 300 FGF19 IHC-
Slide 7: Patient demography and baseline characteristics
Predominantly 2nd line/post-sorafenib patient population IHC+: more MVI* and higher AFP** Patient demography and baseline characteristics 7 Data are preliminary as of data cut off: 18 August 2017 AFP, alpha-fetoprotein; MVI, macrovascular invasion; TACE, transarterial chemoembolisation Parameter, n
Slide 8: BLU-554 pharmacokinetics and pharmacodynamics
Steady state exposure provides Ctrough > Cmin associated with xenograft efficacy Long half life supports QD dosing Blood biomarkers demonstrate consistent pathway modulation BLU-554 pharmacokinetics and pharmacodynamics 8 Data are preliminary as of data cut off: 18 August 2017 PK and PD represent 60
Slide 9: Radiographic response in post-sorafenib HBV-related HCC
Radiographic response in post-sorafenib HBV-related HCC 9 ctDNA, circulating tumor PD, progressive disease; PR, progressive response 0 8 16 24 32 -34% PR -49% PR -49% PR PD Week Baseline Week 16 Baseline ctDNA Measure Baseline Week 8 P53 Q192* Allele fraction 31.1% Undetectable FGF19 amp Copy number
Slide 10: Radiographic response in post-sorafenib non-viral HCC
Radiographic response in post-sorafenib non-viral HCC 10 SD, stable disease 0 8 16 24 32 -26% SD -44% PR -45% PR PD Week Baseline IHC+ Week 16 -44% PR Baseline FISH-
Slide 11: IHC-positivity enriches for radiographic tumor reduction and response
IHC-positivity enriches for radiographic tumor reduction and response 12 *4 confirmed PR; 1 PR/1 CR, unconfirmed Data are preliminary as of data cut off: 18 August 2017 CR, complete response; ORR, overall response rate; PFS, progression-free survival; Best Response n (%) PR; CR 5 (13)*; 1 (3) SD 20
Slide 12: FGF19 IHC+ tumor growth kinetics per prior kinase inhibitor treatment
FGF19 IHC+ tumor growth kinetics per prior kinase inhibitor treatment 12 Data are preliminary as of data cut off: 18 August 2017 Encouraging duration of treatment, particularly in kinase inhibitor naïve patients Previous kinase inhibitor treatment Maximum reduction – sum of diameter % change from ba
Slide 13: Adverse events
Most AEs are Grade 1 or 2: manageable on-target toxicity Adverse events* 13 *Treatment-related adverse events reported in ≥10% patients; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, dose-limiting toxicity 2 DLT at 900 mg (1 Gr 3 fatigue lasting > 7 days; 1
Slide 14: Conclusions
BLU-554 provides acceptable tolerability, pathway engagement and anti-tumor activity in heavily pre-treated FGF19 IHC+ patients Aberrant pathway activation (FGF19 IHC+) demonstrated in ~30% of HCC patients BLU-554 demonstrates clinical activity regardless of HCC etiology and prognostic factors These
Slide 15: Acknowledgements
We thank the participating patients, their families, all study co-investigators, and research co-ordinators at the following institutions: Acknowledgements 15 We also thank Samantha Clark, BSc, of iMed Comms, an Ashfield company, who provided editorial writing support funded by Blueprint Medicines M
Slide 16: References
Llovet JM et al (2016) Nature Reviews Disease Primers 2: 1–23 Miura S et al (2012) BMC Cancer 12:56 Hyeon J et al (2013) Dig Dis Sci 58:1916-1922 Schultze et al. (2015)Nature Genetics 47:505–511 References 16
Blueprint Medicines — Technical Presentation (September 2017) on 6ix